Key result
Six months of pioglitazone treatment induced significant, moderate mitral regurgitation and fluid retention that reversed completely six months after discontinuing the medication.
Why the study?
Does pioglitazone induce reversible mitral regurgitation in a patient with type 2 diabetes?
Case Report (n=1)
No
Does pioglitazone induce reversible mitral regurgitation in a patient with type 2 diabetes?
Six months of pioglitazone treatment induced significant, reversible mitral regurgitation secondary to fluid retention, emphasizing the need for careful cardiac monitoring.
Answers are grounded in this paper and cite their sources.
Pioglitazone may induce reversible mitral regurgitation via fluid retention; single case leaves open causality and need for confirmation.
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
No takes yet. Share an insight, caveat, or question.
Dorkhan et al. (2008) conducted a case report in Type 2 diabetes (n=1). Pioglitazone vs. Baseline/Discontinuation was evaluated on Mitral regurgitation severity and fluid retention markers. Six months of pioglitazone treatment induced significant, moderate mitral regurgitation and fluid retention that reversed completely six months after discontinuing the medication.
Synapse has enriched 10 related papers. Consider them for comparative context: